OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6242$38.3056

Li Kang Biomedical Co Ltd

Food ProcessingVerified

Li Kang Biomedical Co Ltd has a market price of 38.3 TWD per share and a market capitalization of 1,218,208,100 TWD. The company's price-to-earnings ratio is 97.39, which is significantly higher than the typical valuation for the food processing industry, indicating a premium valuation relative to earnings. The price-to-book ratio is 1.4, and the price-to-tangible-book ratio is also 1.4, suggesting that the company's market value is slightly above its book value. The enterprise value to EBITDA ratio is 92.50, and the enterprise value to revenue ratio is 10.62, both of which are elevated compared to industry norms. The company's profitability metrics show a return on equity of 1.44% and a return on assets of 1.17%, which are below the industry median for food processing companies. The operating margin is 11.48%, and the net profit margin is 1.01%, indicating that the company is generating relatively low returns on its operations. The gross profit margin is 68.46%, which is in line with the industry average. Li Kang Biomedical Co Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the latest period is 123,259,000 TWD, and there is no information available on the geographic distribution of this revenue. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.1, indicating that the company is primarily financed through equity. The company's growth trajectory is not clearly defined, as there is no information available on the expected revenue growth for the current or next fiscal year. The company's operating cash flow is 10,600,000 TWD, and its free cash flow is 13,200,000 TWD, indicating that the company is generating positive cash flow from operations. The capital expenditure for the latest period is -2,811,000 TWD, suggesting that the company is not investing heavily in new assets. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is that the company has negative net cash after subtracting total debt, which could impact its ability to meet short-term obligations. The company's liquidity position is supported by a current ratio of 5.28, indicating that it has sufficient current assets to cover its current liabilities. There are no recent events or filings disclosed that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any material changes in its business strategy or operations in the latest reporting period.

30-day price · 6242-0.10 (-0.3%)
Low$36.60High$38.60Close$37.50As of21 May, 00:00 UTC
Profile
CompanyLi Kang Biomedical Co Ltd
Ticker6242.TWO
SectorConsumer Non-Cyclicals
BusinessFood & Beverages
Industry groupFood & Beverages
IndustryFood Processing
AI analysis

Business. Li Kang Biomedical Co Ltd is a food processing company that generates revenue primarily through the production and sale of food products.

Classification. The company is classified under the Consumer Non-Cyclicals economic sector, Food & Beverages business sector, and Food Processing industry, with a classification confidence of 0.92.

Li Kang Biomedical Co Ltd has a market price of 38.3 TWD per share and a market capitalization of 1,218,208,100 TWD. The company's price-to-earnings ratio is 97.39, which is significantly higher than the typical valuation for the food processing industry, indicating a premium valuation relative to earnings. The price-to-book ratio is 1.4, and the price-to-tangible-book ratio is also 1.4, suggesting that the company's market value is slightly above its book value. The enterprise value to EBITDA ratio is 92.50, and the enterprise value to revenue ratio is 10.62, both of which are elevated compared to industry norms. The company's profitability metrics show a return on equity of 1.44% and a return on assets of 1.17%, which are below the industry median for food processing companies. The operating margin is 11.48%, and the net profit margin is 1.01%, indicating that the company is generating relatively low returns on its operations. The gross profit margin is 68.46%, which is in line with the industry average. Li Kang Biomedical Co Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the latest period is 123,259,000 TWD, and there is no information available on the geographic distribution of this revenue. The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.1, indicating that the company is primarily financed through equity. The company's growth trajectory is not clearly defined, as there is no information available on the expected revenue growth for the current or next fiscal year. The company's operating cash flow is 10,600,000 TWD, and its free cash flow is 13,200,000 TWD, indicating that the company is generating positive cash flow from operations. The capital expenditure for the latest period is -2,811,000 TWD, suggesting that the company is not investing heavily in new assets. The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is that the company has negative net cash after subtracting total debt, which could impact its ability to meet short-term obligations. The company's liquidity position is supported by a current ratio of 5.28, indicating that it has sufficient current assets to cover its current liabilities. There are no recent events or filings disclosed that would significantly impact the company's operations or financial position. The company's financial statements do not indicate any material changes in its business strategy or operations in the latest reporting period.
Key takeaways
  • The company is trading at a premium valuation relative to earnings, with a price-to-earnings ratio of 97.39.
  • The company's profitability metrics, including return on equity and return on assets, are below the industry median.
  • The company's capital structure is conservative, with a debt-to-equity ratio of 0.1.
  • The company's liquidity position is supported by a current ratio of 5.28, but it has negative net cash after subtracting total debt.
  • The company's growth trajectory is not clearly defined, and there is no information available on expected revenue growth.
  • The company's risk profile is characterized by a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyTWD
Revenue$123.3M
Gross profit$84.4M
Operating income$14.2M
Net income$12.5M
R&D
SG&A
D&A
SBC
Operating cash flow$10.6M
CapEx-$2.8M
Free cash flow$13.2M
Total assets$1.07B
Total liabilities$199.1M
Total equity$869.3M
Cash & equivalents
Long-term debt$91.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$387.0M$62.0M$51.4M-$2.3M
FY-3$684.3M$137.4M$112.1M$86.9M
FY-2$629.4M$133.4M$111.0M$70.6M
FY-1$565.5M$90.0M$77.0M-$54.9M
FY0$589.2M$98.3M$83.8M-$295.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$616.1M$492.0M
FY-3$688.8M$570.1M
FY-2$827.0M$630.0M
FY-1$1.04B$855.7M
FY0$1.09B$871.2M
PeriodOCFCapExFCFSBC
FY-4$60.4M-$4.4M-$2.3M
FY-3$157.2M-$2.7M$86.9M
FY-2$96.7M-$3.3M$70.6M
FY-1$65.4M-$64.7M-$54.9M
FY0$92.1M-$329.5M-$295.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$123.3M$14.2M$12.5M$13.2M
FQ-6$151.1M$25.7M$21.4M$17.5M
FQ-5$127.3M$19.0M$17.1M$18.0M
FQ-4$163.9M$31.2M$26.0M-$24.0M
FQ-3$134.8M$19.6M$16.9M$932.0k
FQ-2$164.6M$31.4M$25.8M-$56.9M
FQ-1$118.2M$13.2M$13.4M-$143.5M
FQ0$171.6M$34.1M$27.8M-$33.9M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$1.07B$869.3M
FQ-6$1.11B$811.2M
FQ-5$993.4M$829.8M
FQ-4$1.04B$855.7M
FQ-3$1.09B$870.1M
FQ-2$1.12B$831.8M
FQ-1$1.16B$843.6M
FQ0$1.09B$871.2M
PeriodOCFCapExFCFSBC
FQ-7$10.6M-$2.8M$13.2M
FQ-6$10.9M-$10.1M$17.5M
FQ-5$19.9M-$11.9M$18.0M
FQ-4$65.4M-$64.7M-$24.0M
FQ-3$18.4M-$18.8M$932.0k
FQ-2$30.9M-$104.9M-$56.9M
FQ-1$24.9M-$264.8M-$143.5M
FQ0$92.1M-$329.5M-$33.9M
Valuation
Market price$38.30
Market cap$1.22B
Enterprise value$1.31B
P/E97.4
Reported non-GAAP P/E
EV/Revenue10.6
EV/Op income92.5
EV/OCF123.5
P/B1.4
P/Tangible book1.4
Tangible book$869.3M
Net cash-$91.1M
Current ratio5.3
Debt/Equity0.1
ROA1.2%
ROE1.4%
Cash conversion85.0%
CapEx/Revenue-2.3%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food Processing · cohort 1040 companies
Metric6242Activity
Op margin11.5%5.6% medp25 2.1% · p75 11.2%top quartile
Net margin10.1%3.9% medp25 0.5% · p75 8.5%top quartile
Gross margin68.5%23.3% medp25 14.8% · p75 32.6%top quartile
R&D / revenue0.8% medp25 0.5% · p75 2.3%
CapEx / revenue-2.3%-4.1% medp25 -8.9% · p75 -1.9%above median
Debt / equity10.0%37.6% medp25 7.2% · p75 84.5%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 06:44 UTC#50086210
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 01:28 UTCJob: 391ec6ad